# Silo Pharma, Inc.

Silo Pharma, Inc. is a public company headquartered in Sarasota, FL, United States.

## Company overview

- **Legal name:** Silo Pharma, Inc.
- **Former names in filing history:** Uppercut Brands, Inc. (2019-08-13 to 2020-08-14); Point Capital, Inc. (2013-01-30 to 2019-05-14); Gold Swap Inc (2011-03-30 to 2013-01-07)
- **Classification:** Public company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** Sarasota, FL, United States
- **Incorporated in:** NV
- **Fiscal year end:** December 31
- **SEC CIK:** 0001514183

## About

Silo Pharma is a development-stage biopharmaceutical and cryptocurrency company. Its therapeutic research includes SPC-15, an intranasal candidate for post-traumatic stress disorder and stress-induced anxiety, and SP-26, a ketamine-based implant candidate for fibromyalgia and chronic pain. These programs remain investigational. In October 2026, Silo disclosed software and intellectual-property asset purchase agreements, adding a separate technology-related development to its therapeutic research activities. Its reported principal executive office is in Sarasota, FL (United States). For fiscal 2025, ended 2025-12-31, its originally reported results included revenue of USD 72,102; a net loss of USD 4,227,698; cash used in operations of USD 4,661,339. At that year-end, it reported total assets of USD 7,605,100 and cash and cash equivalents of USD 4,748,700.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2025 (period ended 2025-12-31)

- **Revenue:** $72,102 (USD 72,102)
- **Net income:** -$4.2M (USD -4,227,698)
- **Total assets:** $7.6M (USD 7,605,100)
- **Cash and equivalents:** $4.7M (USD 4,748,700)
- **Operating cash flow:** -$4.7M (USD -4,661,339)

### FY2024 (period ended 2024-12-31)

- **Revenue:** $72,102 (USD 72,102)
- **Net income:** -$4.4M (USD -4,392,880)
- **Total assets:** $7.4M (USD 7,411,840)
- **Cash and equivalents:** $3.9M (USD 3,905,799)
- **Operating cash flow:** -$3.8M (USD -3,833,914)

### FY2023 (period ended 2023-12-31)

- **Revenue:** $72,102 (USD 72,102)
- **Net income:** -$3.7M (USD -3,700,683)
- **Total assets:** $7.7M (USD 7,746,141)
- **Cash and equivalents:** $3.5M (USD 3,524,308)
- **Operating cash flow:** -$3.2M (USD -3,224,498)

### FY2022 (period ended 2022-12-31)

- **Net income:** -$3.9M (USD -3,908,551)
- **Total assets:** $11.6M (USD 11,642,877)
- **Cash and equivalents:** $11.4M (USD 11,367,034)
- **Operating cash flow:** -$3.5M (USD -3,497,622)

## Recent SEC filings

- Form 8-K — filed 2026-10-14 — period 2026-10-13 — CURRENT REPORT
- Form 8-K — filed 2026-10-02 — period 2026-10-01 — CURRENT REPORT
- Form 8-K — filed 2026-08-19 — period 2026-08-18 — CURRENT REPORT
- Form 8-K — filed 2026-08-17 — period 2026-08-14 — CURRENT REPORT
- Form 10-Q — filed 2026-08-13 — period 2026-06-30 — QUARTERLY REPORT
- Form 8-K — filed 2026-07-13 — period 2026-07-09 — CURRENT REPORT
- Form DEF 14A — filed 2026-06-30 — period 2026-08-14 — DEFINITIVE PROXY STATEMENT
- Form 8-K — filed 2026-06-18 — period 2026-06-17 — CURRENT REPORT
- Form 8-K — filed 2026-06-03 — period 2026-06-01 — CURRENT REPORT
- Form 8-K — filed 2026-06-01 — period 2026-06-01 — CURRENT REPORT
- Form 10-Q — filed 2026-05-14 — period 2026-03-31 — QUARTERLY REPORT
- Form 8-K — filed 2026-04-02 — period 2026-03-30 — CURRENT REPORT

---

Updated: 2026-10-15T21:34:01.423Z

Canonical page: https://altss.com/profile/silo-pharma-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology